Shareholder alert: weiss law investigates checkmate pharmaceuticals, inc.

New york , april 19, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of checkmate pharmaceuticals, inc. ("checkmate" or the "company") (nasdaq: cmpi), in connection with the proposed acquisition of the company by regeneron pharmaceuticals, inc. (nasdaq: regn), via a tender offer. under the terms of the merger agreement, the company's shareholders will receive $10.50 in cash for each share of checkmate common stock owned.
REGN Ratings Summary
REGN Quant Ranking